MedPath

A clinical trial to study effect of changing Albendazole dose and frequency of administration on W.bancrofti(a filarial worm)microfilaria clearance

Phase 4
Completed
Conditions
Health Condition 1: null- Wuchereia bancrofti infected person
Registration Number
CTRI/2013/10/004113
Lead Sponsor
Regional Medical Research Centre Chandrasekharpur Bhubaneswar
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
100
Inclusion Criteria

Treatment

- Age 18 years to 55 years

- Men and non-pregnant or non-breastfeeding women

- Microfilarial levels >50 mf /ml

- Willingness to spend 3 days in hospital

- Willingness to undergo night time blood draws every 6 months for 2 years

- Ability to understand and sign the informed consent

- Hb levels for inclusion >9 g/dl

- Normal Cr, ALT

Exclusion Criteria

Treatment

â??Non-volunteers

â??Age < 18 years or > 55 years

â??Pregnancy or breast-feeding

â??Hgb <= 9 g/dL

â??Cr > 1.2/100 ml

â??ALT > 30 U

â??Alcohol consumption of more than 2 beers or other alcohol-containing drink/day within a week of each drug administration

â??Serious medical illness

â??History of benzimidazole allergy

â??History of DEC allergy

â??Use of Albendazole or DEC within past 6 months

â??Unwillingness to comply with required study visits

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath